Human Bronchial Smooth Muscle Cells Express Adenylyl Cyclase Isoforms 2, 4, and 6 in Distinct Membrane Microdomains

Amy S. Bogard, Congfeng Xu, and Rennolds S. Ostrom

Department of Pharmacology, University of Tennessee Health Science Center, Memphis, Tennessee

Received December 3, 2010; accepted January 11, 2011

ABSTRACT

Adenylyl cyclases (AC) are important regulators of airway smooth muscle function, because β-adrenergic receptor (AR) agonists stimulate AC activity and increase airway diameter. We assessed expression of AC isoforms in human bronchial smooth muscle cells (hBSMC). Reverse transcriptase-polymerase chain reaction and immunoblot analyses detected expression of AC2, AC4, and AC6. Forskolin-stimulated AC activity was inhibited by G<sub>βγ</sub>-inhibited and G<sub>αy</sub>–stimulated AC activity, consistent with expression of AC6, AC2, and AC4. Isoproterenol-stimulated AC activity was inhibited by Ca<sup>2+</sup> but unaltered by G<sub>αy</sub>, whereas butaprost-stimulated AC activity was stimulated by G<sub>αy</sub> but unaffected by Ca<sup>2+</sup> addition. Using sucrose density centrifugation to isolate lipid raft fractions, we found that only AC6 localized in lipid raft fractions, whereas AC2 and AC4 localized in nonraft fractions. Immunoprecipitation of caveolae using caveolin-1 antibodies yielded Ca<sup>2+</sup>-inhibited AC activity (consistent with expression of AC6), whereas the nonprecipitated material displayed G<sub>αy</sub>-stimulated AC activity (consistent with expression of AC2 and/or AC4). Overexpression of AC6 enhanced cAMP production in response to isoproterenol and beraprost but did not increase responses to prostaglandin E<sub>2</sub> or butaprost. βAR, but not prostanoid EP<sub>2</sub> or EP<sub>4</sub> receptors, colocalized with AC5/6 in lipid raft fractions. Thus, particular G protein–coupled receptors couple to discrete AC isoforms based, in part, on their colocalization in membrane microdomains. These different cAMP signaling compartments in airway smooth muscle cells are responsive to different hormones and neurotransmitters and can be regulated by different coincident signals such as Ca<sup>2+</sup> and G<sub>βγ</sub>.

Introduction

Smooth muscle tone is influenced by extracellular hormones and neurotransmitters, many of which activate G protein-coupled receptors (GPCRs) that modulate the activity of effector enzymes and the level of intracellular second messengers. Intracellular calcium and cAMP, key second messengers of GPCRs, exert opposite effects on smooth muscle contraction, with Ca<sup>2+</sup> causing contraction and cAMP inducing relaxation (Torphy et al., 1982; Billington and Penn, 2003). β-Adrenergic receptor (AR) agonists, which stimulate cAMP production via activation of G<sub>s</sub> and adenylyl cyclase (AC) activity, induce relaxation of smooth muscle (Kume et al., 1994; Kotlikoff and trom and Ehlert, 1999). However, several investigators have found that βAR agonists induce relaxation of airway smooth muscle via both cAMP-dependent and -independent mechanisms, possibly indicating other roles for cAMP signaling (Torphy, 1994; Ostrom and Ehlert, 1998; Spicuzza et al., 2001). In addition, other hormones can regulate cAMP production in smooth muscle via receptors coupled to G<sub>s</sub>. These include prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) and prostacyclin (Madison et al., 1989; Tamaoki et al., 1993). cAMP acts through protein kinase A (PKA) to initiate rapid effects such as regulation of ion channels and cellular metabolism and more delayed effects such as changes in gene expression, growth, and proliferation (Billington et al., 1999; Scott et al., 1999). The exchange protein activated by cAMP, Epac, can also mediate a subset of effects of cAMP in many cells (Grandech et al., 2010). Airway smooth muscle cells also express GPCRs coupled to G<sub>s</sub> and the inhibition of cAMP production, including M<sub>2</mbsc; muscarin acetylcholine receptors, lysophosphatidic acid receptors, and endothelin-1 receptors (Ehler et al., 1997; Hirschman and Emala, 1999).

This work was supported by the National Institutes of Health National Heart, Lung, and Blood Institute [Grant HL079168]. Article, publication date, and citation information can be found at http://jpet.aspetjournals.org. doi:10.1124/jpet.110.177923.

ABBREVIATIONS: GPCR, G protein coupled-receptor; AR, adrenergic receptor(s); AC, adenylyl cyclase; PGE<sub>2</sub>, prostaglandin E<sub>2</sub>; PKA, protein kinase A; hBSMC, human bronchial smooth muscle cell(s); RT, reverse transcriptase; PCR, polymerase chain reaction; ELISA, enzyme immunoassay; PBS, phosphate-buffered saline; DTT, dithiothreitol; PAGE, polyacrylamide gel electrophoresis; IPR, prostacyclin receptor(s); IP, immunoprecipitated; PKC, protein kinase C.
Nine different transmembrane AC isoforms exist, each with different amino acid sequences, tissue and chromosomal distribution, and regulation (Hurley, 1999; Hanoune and Defer, 2001). Differences in regulation include stimulation or inhibition by Gp120, Ca2+, and various protein kinases. AC5 and AC6 represent a subfamily of ACs related in structure and regulation. These isoforms are inhibited by PKA, Ca2+, nitric oxide, Gs, and Gt (McVey et al., 1999; Hill et al., 2000; Hanoune and Defer, 2001). In contrast, AC3 can be either stimulated by Ca2+/calmodulin or specifically inhibited by calmodulin kinase II, whereas AC2 is activated by Gq (Wei et al., 1996; Hanoune and Defer, 2001). Although these unique properties of AC isoforms have been recognized for some time (on the basis of reconstituted enzymatic assays), the effects these features have on cell physiology are poorly understood (Sadana and Dessauer, 2009). One possible reason for this is the fact that most cells express at least three or four different AC isoforms, implying a high degree of duplicity (Ostrom and Insel, 2004). In addition, all AC isoforms are activated by the same G protein, and there are no good isoform-specific drugs, making it difficult to activate select AC isoforms.

It is becoming a commonly accepted notion that various proteins involved in GPCR signal transduction are enriched and spatially organized within plasma membrane microdomains (Neubig, 1994; Steinberg and Brunton, 2001; Ostrom, 2002). Numerous studies have focused on caveolae and lipid rafts as membrane microdomains where receptors, G proteins, effector molecules, and even second messengers are concentrated (Shaull and Anderson, 1998; Davare et al., 2001; Ostrom and Insel, 2004). Caveolae are cholesterol- and sphingolipid-enriched portions of the membrane that form distinct flask-like invaginations when the protein caveolin is expressed (Anderson, 1998). Lipid rafts are microdomains of the plasma membrane that are biochemically similar to caveolae but morphologically indistinguishable from the rest of the plasma membrane (Hooper, 1999; Simons and Toomre, 2000; Galbiati et al., 2001). We have previously reported that compartmentation of GPCR signaling may be a means by which cells target specific hormonal signals to distinct cellular responses despite using similar signaling pathways (Ostrom et al., 2001; Liu et al., 2008). One means by which this may occur is through the distinct localization of AC isoforms in either lipid raft or nonraft domains.

Our goal was to define the AC isoforms expressed in hBSMC, a convenient cell model of human airway smooth muscle. We also sought to characterize the localization of these proteins in membrane microdomains and define the regulation of their activity by key receptors. We found that hBSMC express primarily AC2, AC4, and AC6. AC6 localizes in caveolin-rich lipid raft fractions where it is stimulated by β2AR and prostacyclin receptors and inhibited by Ca2+, whereas AC2 and AC4 expression is excluded from these domains and is regulated by prostanooid EP2 receptors and stimulated by Gp120.

---

**Materials and Methods**

**Materials and Cell Culture.** The primary antibody for FLAG (monoclonal) was obtained from Sigma-Aldrich. Primary antibodies for caveolin-1 (monoclonal), caveolin-2 (monoclonal), and caveolin-3 (monoclonal) were obtained from BD Biosciences (San Jose, CA). Primary antibodies for AC2 (polyclonal), AC3 (polyclonal), AC4 (polyclonal), AC5/6 (polyclonal), AC7 (polyclonal), β2-adrenergic receptor (polyclonal), EP2 receptor (polyclonal), and EP4 receptor (polyclonal) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Secondary antibodies were obtained from Santa Cruz Biotechnology, Inc. Beraprost and butaprost were obtained from Cayman Chemical (Ann Arbor, MI). Purified bovine Gp120 protein was purchased from EMD Biosciences (San Diego, CA). All other chemicals and reagents were obtained from Sigma-Aldrich.

hBSMC were obtained from LonzaBio (Basel, Switzerland) and were maintained in smooth muscle basaI medium supplemented with the SmGM-2 bullet kit (5% fetal bovine serum, 0.1% insulin, 0.1% human epidermal growth factor, 0.2% human fibroblast growth factor-B, and gentamicin sulfate/amphotericin B; LonzaBio) and kept in a 37°C incubator with 5% CO2. Cells were used between passages 4 and 12 for all experiments. In some studies, cells were incubated with approximately 100 viral particles per cell of recombinant adenoviruses expressing either the lacZ cDNA (control) or the murine AC6 cDNA. Cells were incubated with adenovirus for 24 h and then were washed and equilibrated in growth medium for 24 h before assays were performed. Preliminary studies using lacZ adenovirus and β-galactosidase staining indicated that the efficiency of the adenoviral gene transfer was greater than 90% (data not shown).

**RT-PCR.** RT-PCR for AC isoforms was performed using the primer pairs described in Table 1. Total RNA was extracted from WI-38 cells grown to 80 to 90% confluence on 10-cm plates using TRIzol reagent (Invitrogen, Carlsbad, CA) and an RNaseasy RNA isolation kit (QiAGEN, Valencia, CA). A DNase reaction was performed to eliminate DNA contaminants, and the RNA was reverse transcribed using Superscript II (Invitrogen) and poly[dT] primer. PCR with each primer pair were performed on cDNA, genomic DNA (positive control), and minus RT (negative control) templates. The primers were designed on the basis of GenBank sequences and are listed in Table 1. The thermal profile for all real-time PCR was 50°C for 2 min and 95°C for 10 min, followed by 35 cycles of 95°C for 10 s and 60 to 62°C for 1 min. PCR products were analyzed by agarose gel electrophoresis and visualized under UV light with ethidium bromide.

**Measurement of cAMP Accumulation.** hBSMC were washed three times with serum- and NaHCO3-free Dulbecco’s modified Eagle’s medium supplemented with 20 mM HEPES, pH 7.4, and equilibrated for 30 min. An assay for cAMP accumulation was performed by incubation with drugs of interest and 0.2 mM isobutylmethylxanthine, a phosphodiesterase inhibitor, for 10 min. To terminate reactions, assay medium was aspirated, and 250 μl of ice-cold trichloroacetic acid (7.5% w/v) was immediately added to each well. cAMP content in trichloroacetic acid extracts was determined by EIA (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Production of cAMP was normalized to the amount of protein per sample as determined using a dye-binding protein assay (Bio-Rad Laboratories, Hercules, CA).

**Measurement of AC Activity.** AC and nitric-oxide synthase activities were measured in membranes prepared from neonatal rat ventricular myocytes. Cells were rinsed twice in ice-cold phosphate-buffered saline.

---

**TABLE 1**

<table>
<thead>
<tr>
<th>Isomorph</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>AC1</td>
<td>ACTACGAAGCTGAGAACCCGAAAA</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC2</td>
<td>GAGCCCCCTGCTTAAAA</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC3</td>
<td>CTGAGCGAGTAGCTCAAGACGAAGGC</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC4</td>
<td>ATCCATACCGGCTTCTGAGAAGGC</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC5</td>
<td>CTGAGCGAGTAGCTCAAGACGAAGGC</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC6</td>
<td>CGGAGTGGTGAACATGAGAGTCG</td>
<td>CCTTCTCCTGCAAGATCTCAC</td>
</tr>
<tr>
<td>AC7</td>
<td>AGAGCTGGCCAAGAGACTCA</td>
<td></td>
</tr>
<tr>
<td>AC8</td>
<td>ACTACGAGGTAGAACCGGGT</td>
<td></td>
</tr>
<tr>
<td>AC9</td>
<td>GAACTGCAGAACTGACATG</td>
<td></td>
</tr>
</tbody>
</table>

---

Some sequences were adapted from Xu et al. (2001).

---

**RT-PCR.** RT-PCR for AC isoforms was performed using the primer pairs described in Table 1. Total RNA was extracted from WI-38 cells grown to 80 to 90% confluence on 10-cm plates using TRIzol reagent (Invitrogen, Carlsbad, CA) and an RNasey RNA isolation kit (QiAGEN, Valencia, CA). A DNase reaction was performed to eliminate DNA contaminants, and the RNA was reverse transcribed using Superscript II (Invitrogen) and poly[dT] primer. PCR with each primer pair were performed on cDNA, genomic DNA (positive control), and minus RT (negative control) templates. The primers were designed on the basis of GenBank sequences and are listed in Table 1. The thermal profile for all real-time PCR was 50°C for 2 min and 95°C for 10 min, followed by 35 cycles of 95°C for 10 s and 60 to 62°C for 1 min. PCR products were analyzed by agarose gel electrophoresis and visualized under UV light with ethidium bromide.

**Measurement of cAMP Accumulation.** hBSMC were washed three times with serum- and NaHCO3-free Dulbecco’s modified Eagle’s medium supplemented with 20 mM HEPES, pH 7.4, and equilibrated for 30 min. An assay for cAMP accumulation was performed by incubation with drugs of interest and 0.2 mM isobutylmethylxanthine, a phosphodiesterase inhibitor, for 10 min. To terminate reactions, assay medium was aspirated, and 250 μl of ice-cold trichloroacetic acid (7.5% w/v) was immediately added to each well. cAMP content in trichloroacetic acid extracts was determined by EIA (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Production of cAMP was normalized to the amount of protein per sample as determined using a dye-binding protein assay (Bio-Rad Laboratories, Hercules, CA).

**Measurement of AC Activity.** AC and nitric-oxide synthase activities were measured in membranes prepared from neonatal rat ventricular myocytes. Cells were rinsed twice in ice-cold phosphate-buffered saline.

---

**TABLE 1**

<table>
<thead>
<tr>
<th>Isoform</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>AC1</td>
<td>ACTACGAAGCTGAGAACCCGAAAA</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC2</td>
<td>GAGCCCCCTGCTTAAAA</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC3</td>
<td>CTGAGCGAGTAGCTCAAGACGAAGGC</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC4</td>
<td>ATCCATACCGGCTTCTGAGAAGGC</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC5</td>
<td>CTGAGCGAGTAGCTCAAGACGAAGGC</td>
<td>GAACTGCAGAACTGACATG</td>
</tr>
<tr>
<td>AC6</td>
<td>CGGAGTGGTGAACATGAGAGTCG</td>
<td>CCTTCTCCTGCAAGATCTCAC</td>
</tr>
<tr>
<td>AC7</td>
<td>ACTACGAGGTAGAACCGGGT</td>
<td></td>
</tr>
<tr>
<td>AC8</td>
<td>AGAGCTGGCCAAGAGACTCA</td>
<td></td>
</tr>
<tr>
<td>AC9</td>
<td>GAACTGCAGAACTGACATG</td>
<td></td>
</tr>
</tbody>
</table>

---

Some sequences were adapted from Xu et al. (2001).
buffered saline (PBS) and then were scraped into hypotonic homogenizing buffer (30 mM Na-HEPES, 5 mM MgCl₂, 1 mM EGTA, and 2 mM DTT, pH 7.5) and homogenized with 20 strokes of a Dounce homogenizer. The homogenate was centrifuged at 300g for 5 min at 4°C; the supernatant was then transferred to a centrifuge tube and centrifuged at 5000g for 10 min. The pellet was suspended in buffer (30 mM Na-HEPES, 5 mM MgCl₂, and 2 mM DTT, pH 7.5) to attain approximately 1 mg/ml total protein concentration before being added to tubes containing drug and AC assay buffer (30 mM Na-HEPES, 100 mM NaCl, 1 mM EGTA, 10 mM MgCl₂, 1 mM isobutylmethylxanthine, 1 mM ATP, 10 mM phosphocreatine, 5 μM GTP, 60 U/ml creatine phosphokinase, and 0.1% bovine serum albumin, pH 7.5). AC activity assays were terminated after 15 min by boiling and CAMP content was determined by EIA (GE Healthcare).

In other studies, AC activity was measured in caveolin-1 immunoprecipitates. Cells were scraped and homogenized in a modified lysis buffer with 1% Triton X-100 (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl₂, 1 mM EGTA, 2 mM DTT, and 1% Triton X-100 plus mammalian protease inhibitor cocktail (Sigma Aldrich)) and homogenizing by sonication. The homogenate were pre-cleared with 50 μl of protein A-agarose and resuspended in membrane buffer. The assay was conducted by adding 30-μl sample (membranes or immunoprecipitate) to tubes containing assay buffer (30 mM Na-HEPES, 100 mM NaCl, 1 mM EGTA, 10 mM MgCl₂, 1 mM isobutylmethylxanthine, 1 mM ATP, 10 mM phosphocreatine, 5 μM GTP, 60 U/ml creatine phosphokinase, and 0.1% bovine serum albumin, pH 7.5.) and cAMP content was determined by EIA (GE Healthcare).

Results

Because AC isoforms possess different regulatory properties and can be compartmentalized in specific signaling microdomains, we sought to define the AC isoforms expressed in hBSMC. We used RT-PCR analysis with isoform-specific primers to detect mRNA for each of the nine mammalian AC isoforms. We detected mRNA for AC2, AC4, and AC6 from hBSMC (Fig. 1). Each of these primer pairs amplified appropriately sized DNA sequences but did not yield PCR products when RNA (samples not treated with reverse transcriptase) was used as the template (data not shown). Because most primer pairs produced some nonspecific bands, we used two different template concentrations to confirm that only primers for AC2, AC4, and AC6 yielded specific product. Primers for other AC isoforms yielded products that were not of the expected size or sequence.

We also conducted immunoblot analyses to detect expression of AC isoforms and to determine the localization of these isoforms in plasma membrane microdomains. We fractionated hBSMC using a nondetergent method to isolate caveolin-rich lipid raft fractions and performed immunoblot analyses with AC isoform-specific antibodies. hBSMC express caveolin-1 and caveolin-2 but not caveolin-3 in buoyant lipid raft fractions and whole-cell lysates (Fig. 2). Only trace im-
munoreactivity for caveolins could be detected in nonraft fractions. AC isoform-specific antibodies detected multiple nonspecific bands, but only bands of the expected molecular weights were considered positive. We detected immunoreactivity for AC2, AC4, and AC5/6 using an antibody unable to distinguish between AC5 and AC6 in hBSMC (Fig. 2). AC2 and AC4 immunoreactivity was detected only in nonraft fractions, whereas immunoreactivity for AC5/6 was detected only in lipid raft fractions. We could not detect immunoreactivity for any of the other AC isoforms.

RT-PCR and immunoblot analyses did not yield definitive information about the predominant AC isoforms expressed. Thus, we measured AC activity in membranes and probed for characteristic regulatory properties to determine the predominant AC isoform(s) in hBSMC. Membrane AC activity was stimulated above basal levels by addition of either forskolin (direct activator of AC, 10 μM), isoproterenol (βAR agonist, 1 μM), beraprost [prostacyclin receptor (IPR) agonist, 1 μM] or butaprost (EP2 receptor agonist, 1 μM) (Fig. 3). Addition of 1 μM calcium caused no significant change in basal, forskolin-stimulated, beraprost-stimulated, or butaprost-stimulated AC activity but did inhibit isoproterenol-stimulated activity. These data imply that β-adrenergic receptors couple to a calcium-inhibitable AC isoform. In contrast, addition of 200 nM purified G protein increased enzymatic activity in the presence of either forskolin or beraprost but had no significant effect on other conditions. Thus, total membrane AC activity (forskolin) and EP2 receptor responses are sensitive to G protein. These data are consistent with expression of both a calcium-inhibitable AC isoform (AC6) and a G protein-stimulated isoform (AC2 and AC4), with the latter type being the predominant isoform.

The receptor-selective effects of calcium and G protein on AC activity and the localized expression of AC isoforms led us to hypothesize that lipid raft AC expression would display regulatory properties distinct from that in nonraft fractions. Therefore, we immunoprecipitated (IP) caveolin-1 from hBSMC using a modified protocol that maintains the integrity of the lipid raft domain and supports AC enzymatic activity (Ostrom et al., 2001; Liu et al., 2008). This method is essentially an immunosololation of caveolae. As we have observed in other cells, these immunoprecipitates contain AC5/6 immunoreactivity (Fig. 4, top) (Ostrom et al., 2001, 2004; Liu et al., 2008). We detected low levels of AC22 immunoreactivity in both IP and supernatant fractions and found that both contained forskolin-stimulated AC activity (Fig. 4, bottom). The addition of 1 μM calcium inhibited forskolin-stimulated AC activity in the caveolin-1 IP samples but had no effect in the IP supernatant. Inclusion of 200 nM purified G protein had no effect on AC activity in the caveolin-1 IP samples but stimulated activity in the IP supernatant. Because calcium-stimulable AC isoforms (AC1, AC3, and AC8) require calmodulin, we
either vehicle, 1 mM free Ca\(^{2+}\), 200 nM purified \(G_{\beta\gamma}\), or 1 mM Ca\(^{2+}\) plus 1 mM calmodulin (CaM). Data are presented as the mean ± S.E.M. of \(n = 5\). #, \(p < 0.05\) by paired \(t\) test compared with vehicle alone; *, \(p < 0.05\) by paired \(t\) test compared with 10 μM forskolin alone.

We next wondered how altering the endogenous AC isoform expression would change signaling. We measured cAMP production in hBSMC that had been incubated with recombinant adenoviruses expressing either lacZ (control) or AC6 genes. Whereas basal cAMP accumulation did not differ between control cells and cells overexpressing AC6, AC6 overexpression enhanced responses to forskolin (10 μM) or isoproterenol (1 μM) 3- to 4-fold compared with that in control cells (Fig. 5A). cAMP accumulation stimulated by butaprost (1 μM) was enhanced almost 2-fold by AC6 overexpression. In contrast, responses to other agonists that increase cAMP in hBSMC, including PGE\(_2\) (10 μM) and butaprost (1 μM), were unchanged in cells overexpressing AC6. We examined the cAMP response across a range of concentrations for each of these receptor-selective agonists. AC6 overexpression increased the \(E_{\text{max}}\) of isoproterenol and beraprost approximately 3-fold without significantly altering the potency of these responses (Fig. 5, B and C). Neither the potency nor the efficacy of butaprost-stimulated cAMP production was altered by AC6 overexpression (Fig. 5D). Thus, AC6 overexpression in hBSMC selectively enhanced cAMP generation by βAR and IPR but not by other G\(_{\text{q}}\)-coupled receptors.

In other cell types, AC6 overexpression selectively enhances βAR- and IPR-mediated cAMP accumulation because of the compartmentation of AC6 with these receptors in lipid rafts (Liu et al., 2008). We tested the hypothesis that lipid raft microdomains may be one site for the βAR-AC6 colocalization in hBSMC. We isolated lipid raft fractions from hBSMC using the same method as described for Fig. 2. Caveolin-1 was enriched in the buoyant, lipid raft fractions as was virtually all of the AC5/6 immunoreactivity when AC6 was overexpressed (Fig. 6). We detected endogenously expressed β2AR in both lipid raft fractions and nonraft fractions. Multiple β2AR immunoreactive bands were detected in nonraft and whole-cell lysate fractions, making interpretation difficult. Therefore, we overexpressed an epitope-tagged β2AR using a recombinant adenovirus. Immunoblotting for the FLAG epitope showed that the bulk of β2AR are localized in lipid raft fractions. In contrast, immunodetection of native prostanoid EP\(_{3}\) and EP\(_{4}\) receptors occurred only in noncaveolin-rich, nonraft fractions. Taken together, these results imply that β2AR, IPR, and AC6 colocalize in lipid rafts and that this microdomain excludes prostanoid E receptors and the other principle AC isoforms of hBSMC (AC2 and AC4).

We used AC activity assays in caveolin-1 IP samples as an alternative approach to confirm the selective localization and coupling of GPCRs and AC isoforms observed above. In these studies, we immunoprecipitated caveolin-1 from lacZ (control) cells or cells overexpressing AC6 and measured AC activity in response to receptor-selective agonists. Caveolin-1 IP samples contained forskolin- and isoproterenol-stimulated AC activity but no significant stimulation by beraprost or butaprost (Fig. 7A). Caveolin-1 IP samples from AC6-overexpressing cells possessed 1.5- to 2-fold higher AC activity when stimulated with forskolin or isoproterenol (compared with control cells). However, no significant increase in AC activity could be detected in response to beraprost and butaprost. We also examined AC activity in the IP supernatants. In these fractions, forskolin increased AC activity approximately 4-fold in both lacZ and AC6 cells (Fig. 7B). However, we could not observe increased AC activity in supernatants stimulated with isoproterenol, butaprost, or beraprost. Thus, IP supernatants contain significant AC activity, of which none appears to be from AC6, and do not retain any GPCR-stimulable activity. Taken together, these data confirm that AC6 overexpression localizes to lipid rafts and/or caveolae where it can be selectively activated by β2AR.

**Discussion**

The objective of these studies was to characterize the AC isoforms expressed in hBSMC and to define their localization and coupling to specific receptors. We used several approaches to define the AC isoforms expressed, including RT-PCR, immunoblot analysis, and characterization of the iso-
form-specific regulatory properties of AC activity in hBSMC. Our data indicate that hBSMC express three isoforms of AC: AC2, AC4, and AC6. AC2 and AC4, both isoforms stimulated by Gαi/H9252/H9253, appear similar in that they are expressed in nonlipid raft membrane fractions where they colocalize with and couple to EP2 receptors. The specific coupling of EP2 receptors with AC2/4 seems to impart a Gαi/H9252/H9253-stimulable but Ca2+/H11001-insensitive profile of cAMP signaling stimulated by PGE2. In contrast, AC6 is expressed in lipid raft domains of hBSMC where this protein is colocalized with at least a portion of the cell’s complement of β2AR. The lipid raft-localized AC activity is Ca2+/H11001-sensitive but not altered by Gαi, imparting a Ca2+/H11001 sensitivity to the βAR agonist-stimulated cAMP signaling. These data are consistent with compartmentalized cAMP signaling that is imparted by distinct AC isoform localization and coupling to colocalized receptors. Airway smooth muscle may interpret catecholamine (via βAR) and PGE2 (via EP2 receptors) signals differently because of this compartmentalized cAMP accumulation and differential regulation by coincident signals (Ca2+/H11001 and Gαi). More work is needed to determine whether the cellular responses to these hormones differ, but it is clear that both βAR agonists and PGE2 have both common and divergent effects in smooth muscle (Madison et al., 1989; Yan et al., 2010). Figure 8 is a schematic diagram that summarizes the localization and signaling mechanisms we propose on the basis of our findings.

One approach we used was to immunoprecipitate caveolin-1 in reduced detergent conditions that maintain lipid raft integrity. Under these conditions, immunoprecipitation of caveolin-1 pulls down the entire caveolar microdomain with lipids, cholesterol, and associated proteins (Ostrom et al., 2001; Liu et al., 2008). These samples are essentially immu-
no isolated caveolae and have an advantage over other lipid raft/caveolar isolation methods in that most enzymatic activity persists through the isolation. We have used this approach in other cell types to measure AC activity regulated by different receptors (Liu et al., 2008). In the present studies, we used this method to also determine the AC isoform-specific regulation of cAMP production in these membrane microdomains. Our data are consistent with the idea that AC2 and AC4 reside outside the lipid raft/caveolar microdomain where they couple primarily to EP2 receptors, but that AC6 (endogenous and overexpressed) resides in caveolae where it can be regulated by prostacyclin receptors. We used an overexpression approach to measure the isoform-specific effects of AC. Overexpression of AC6 enhanced signaling by β2AR or prostacyclin receptor activation but did not affect responses to EP2 receptors. This observation was consistent across both whole-cell cAMP accumulation studies and assays of AC activity in caveolin-1 IP samples and supernatants. The fact that β2AR (both native and overexpressed) were observed in the same lipid raft fractions as the overexpressed AC6 but that EP2 and EP4 receptors were excluded from these domains seemingly corroborates these findings. Prostacyclin receptors have been shown to localize in lipid raft domains in other cell types (Liu et al., 2008). Although we were unable to detect these receptors using available antibodies, the fact that beraprost-stimulated cAMP production was enhanced by AC6 overexpression implies that prostacyclin receptors are also lipid raft-localized in hBSMC.

At first glance, the AC isoforms expressed by hBSMC that we report appear different from those previously reported in studies of airway smooth muscle and primary cultured cells isolated from human samples (Xu et al., 2001). Xu et al. (2001) detected mRNA for AC isoforms 1, 3, 4, 5, 6, 7, and 9. They performed immunoblot analysis on whole-cell lysates and detected expression of just AC5/6 (using the same antibody used here, which is unable to distinguish between these two isoforms). To determine the predominant AC isoform, they examined cAMP production in intact cells for regulation by protein kinase C (PKC) and PKA. These authors concluded that the predominant AC isoform was probably AC5, because cAMP production was inhibited by PKA activation but stimulated by treatment with phorbol ester (an activator of PKC). Given that Xu et al. (2001) could not detect AC2 or AC4 by immunoblot, their conclusions were logical because AC6 activity is inhibited by PKC. However, the AC activity profile they observed could also be explained by expression of both AC2/4 with AC6, consistent with our present findings. The fact that Xu et al. (2001) did not enrich their protein samples via lipid raft fractionation, as in the present studies, makes it possible that they missed the expression of AC2 and AC4 at the protein level. Thus, our data may not be inconsistent with those reported by Xu et al. (2001), even though the sources of the cells differ between these studies.

The characterization of AC isoforms in the present report

Fig. 7. Adenylyl cyclase activity in immunoisolated caveolae or isolation supernatants from hBSMC overexpressing AC6. Caveolae were immuno-isolated from hBSMC by immunoprecipitating caveolin-1 (Cav1) in reduced detergent conditions (see Materials and Methods). Cav1 IP samples (A) or IP supernatants (B) were collected from hBSMC incubated for 24 h with recombinant adenoviruses expressing either lacZ (□) or AC6 (■), then incubated with either vehicle (basal), forskolin (Fsk), isoproterenol (Iso), beraprost (Bera), or butaprost (Buta). Data are presented as the mean ± S.E.M. of n = 3. †, p < 0.05 by paired t test compared with basal; ††, p < 0.05 by paired t test compared with lacZ.

Fig. 8. Schematic diagram of GPCR/AC localization and signaling in hBSMC. β2AR and IPR signal via AC6 primarily in lipid raft microdomains. Ca2+ appears to inhibit these signals, whereas Gs has no effect. In nonraft membranes, prostanoid EP2 receptors localize with AC2 and AC4 and signal via a Ca2+-insensitive cyclase that is Gs stimulated. The dashed line represents a presumed barrier between the two illustrated cAMP compartments.
depends heavily on immunological approaches, which can present significant pitfalls. Foremost, the commercially available antibodies for AC isoforms are varied in their usefulness and their degree of nonspecificity. In our experience, the antibodies for AC2, AC3, AC4, and AC5/6 are relatively reliable (we have rarely detected expression of AC7 in the cells we have analyzed). Use of these antibodies to characterize AC isoforms in cultured cells depends on concentrating cell lysates to maximize detection and then fractionating cells to separate lipid raft and nonraft microdomains, which splits many of the nonspecific bands into different fractions and facilitates identification. We mitigate the shortcomings of using these antibodies by also analyzing mRNA expression and the enzymatic activity characteristic of each AC isoform (Figs. 1, 3, and 4). However, other pharmacological approaches for defining AC isoform expression are available and are particularly applicable for characterizing AC isoforms in tissues, whereas using these antibodies is more problematic. AC isoforms can be defined by rank order of sensitivity to various nucleotide and non-nucleotide inhibitors or by activation by isoform-selective derivatives of forskolin (Gille et al., 2004; Pinto et al., 2008; Gottle et al., 2009). Where no single approach can be used to reliably characterize the AC isoforms expressed in a given system, a combination of molecular and pharmacological tools can be deployed to achieve this goal.

It will be particularly important to understand the AC isoform expression and localization in airway smooth muscle from patients with asthma or chronic obstructive pulmonary disease. Furthermore, it is not known whether the human population is heterogeneous with respect to AC isoform expression in airway smooth muscle. Therefore, more work needs to be done before one can generalize about the AC isoforms expressed across patient populations. Our data define AC isoform expression in a convenient cell culture model of airway smooth muscle but also highlight how the cellular response to hormones and neurotransmitters such as catecholamines and prostaglandins can be largely influenced by the AC isoforms expressed by the cells. If development, age, or disease induces changes in AC expression, the cAMP signaling by airway smooth muscle could be altered significantly. In addition, if patients differ in their AC isoform expression profile they might display divergent responses to drugs such as βAR agonists, phosphodiesterase inhibitors, or cyclooxygenase inhibitors. Our data may also provide an impetus for ongoing work to develop AC isoform-specific inhibitors or activators, because such drugs could allow alteration of signaling by a subset of the cell’s receptors (Onda et al., 2001; Mou et al., 2006). Such agents may have two advantages over traditional receptor-targeting drugs: 1) they may be more specific because receptors initiate other signaling cascades in addition to the canonical second messengers, and 2) they may have greater efficacy because AC expression is the stoichiometrically limiting component in the pathway (Daaka et al., 1998; Ostrom et al., 2000).

In conclusion, we detected expression of three AC isoforms, AC2, AC4, and AC6, in human airway smooth muscle cells in culture. This pattern of expression probably does not differ from that of primary cultures from human airways (Xu et al., 2001), indicating that this cultured cell model is appropriate for examining GPCR signaling and regulation that is relevant to humans. Different hormone receptors appear to couple to distinct AC isoforms, based largely on their colocalization in membrane microdomains, and their regulation of cAMP signaling is sensitive to different factors that affect the activity of these specific AC isoforms. More work is required to understand how (and whether) cAMP signaling in these different microdomains leads to unique patterns of cellular regulation. Given that cAMP signaling is known to be compartmentalized by expression of phosphodiesterases and A kinase anchoring proteins (Michel and Scott, 2002; Dessauer, 2009), we predict that such signaling microdomains are relevant to airway physiology and disease.

Acknowledgments

We thank Joseph Kaminsky and Fengying Li for their technical assistance with these studies.

Authorship Contributions

Participated in research design: Bogard, Xu, and Ostrom.

Conducted experiments: Bogard, Xu, and Ostrom.

Performed data analysis: Bogard, Xu, and Ostrom.

Wrote or contributed to the writing of the manuscript: Bogard and Ostrom.

Other: Ostrom acquired funding for the research.

References


Address correspondence to: Dr. Rennolds S. Ostrom, Department of Pharmacology, University of Tennessee Health Science Center, 874 Union Ave., Crowe 115, Memphis, TN 38163. E-mail: rostrom@uthsc.edu